Skip links
Engineering Drug Development Through Predictive Intelligence

From Molecular Uncertainty to Clinical Precision

We identify high-value therapeutic opportunities and systematically transform them into development-ready assets through predictive modelling, formulation engineering, and translational strategy.

Not discovery for its own sake—but engineering what already works into what is clinically viable.

Drug development does not fail for lack of biology—it fails at translation

Across therapeutic areas, the same pattern repeats: molecules demonstrate strong biological rationale, early signals are promising, yet clinical success remains inconsistent.

The failure point is rarely discovery.

It lies in:
  • Poor predictability of human pharmacokinetics
  • Inadequate formulation strategies
  • Fragmented CMC and regulatory alignment
We exist to solve this exact problem

A unified system for drug development

Every programme at Dhee is built through an integrated framework:

INPUT

Scientific Insight

Intelligence

SynapTx Layer

Engineering

Formulation

Strategy

Translational

Output

Clinical-Ready Asset

This is not a linear process—it is a structured, iterative system designed to reduce uncertainty at every stage.

A portfolio built on solving high-value bottlenecks
Molecule Rescue Platforms

Unlocking clinically validated molecules limited by delivery and formulation barriers.

Includes
Biology works—but delivery fails
Delivery & Exposure Engineering Platforms

Engineering precise pharmacokinetics and controlled activation.

Includes
Exposure is unpredictable and poorly controlled
Translational Systems & Microenvironment Engineering

Redefining how drugs interact with complex biological environments.

Includes
Biology is structurally inaccessible
SynapTx — The Intelligence Core

A proprietary intelligence layer that transforms fragmented scientific data into actionable development strategy.

Capabilities:
  • Predictive pharmacokinetic modelling
  • Evidence synthesis across literature and patents
  • Formulation and stability prediction
  • Development pathway optimisation
This is the layer that connects every platform.
A single philosophy across multiple domains
Clinically Relevant, Not Hypothetical

We focus on known molecules, validated mechanisms, and real therapeutic gaps—not speculative targets.

Validated Mechanisms
Real Gaps
Known Molecules
Bottleneck-Driven Selection

We prioritise opportunities where failure is driven by delivery limitations, stability constraints, or translational gaps—not scientific novelty alone.

Delivery Limits
Stability
Translational Gaps
Engineering-Led Solutions

We solve through advanced formulation science, predictive modelling, and integrated CMC and regulatory strategy.

Formulation Science
Predictive Modelling
CMC & Regulatory
Engineering delivery beyond formulation

We do not rely on a single technology. Each programme is approached through a multi-layered delivery engineering framework, designed to solve the specific bottleneck limiting clinical translation.

01

 
Microenvironment Engineering

 

  • Stabilising highly reactive intermediates (e.g., HNO donors)
  • Creating protected internal environments within carriers
  • Modulating tissue architecture to enhance penetration

Not just delivery—but control over where and how drugs behave

02

 
Controlled & Sustained Release Architectures

 

  • Injectable depots (hydrogels, microspheres)
  • Matrix-driven release systems
  • Multi-phase release profiles (immediate + sustained)

Bolus dosing → predictable pharmacokinetics

03

 
Targeted & Triggered Activation Systems

 

  • Enzyme-responsive systems (MMP, esterase-triggered)
  • Tumour or disease microenvironment activation
  • Masked prodrugs and linker-based activation

Converting systemic toxicity into localised precision

04

 
Precision Dosing & Exposure Control

 

  • Metered micro-dosing architectures
  • Transdermal and alternative delivery systems
  • Controlled permeation and absorption kinetics

Transforming inconsistent therapies into reproducible interventions

05

 
Solubility & Stability Engineering

 

  • Advanced solubilisation strategies
  • Encapsulation (where appropriate—not assumed)
  • Excipient system optimisation
  • Protection against degradation pathways

Molecules that remain stable, bioavailable, and manufacturable

06

 
Platform-Agnostic Integration

 

  • ADCs combining biologics + linker chemistry + CMC control
  • Prodrugs requiring masking + activation + solubility engineering
  • ECM systems integrating materials science + biology + delivery
 

The output is not a formulation—it is a complete translational system

We do not optimise formulations.

We engineer how molecules survive, move, activate, and perform in real biological systems.

Execution, Not Just Insight

Insight is only valuable if it translates into reality

Unlike purely computational or advisory approaches, we deliver across every stage.

Design the Strategy

Evidence synthesis, PK modelling, and development pathway selection.

Engineer the Formulation

Applied formulation science from concept through to manufacturable system.

Align with Regulation

CMC and regulatory strategy integrated from the outset, not retrofitted.

Enable Real-World Execution

From concept to clinic—not just concept to report.

Collaboration Model

Multiple pathways to partnership

Co-Development

  • Joint programme design
  • Shared development strategy
  • Long-term partnership

  • Engineer the Formulation

  • Re-engineering stalled or failed assets
  • Reformulation and repositioning

  • Platform Integration

  • Applying SynapTx to partner pipelines
  • Enhancing internal R&D decision-making

  • Technology Co-Creation

  • Novel delivery systems
  • Translational strategy development

  • Collaboration Model

    We operate where most pipelines break down

    WELL-ESTABLISHED

    Discovery

    Clinical Trials

    The Space In Between

    Is where
    we operate

    UNDER-ENGINEERED

    PK & Translation

    Formulation Strategy

    CMC Alignment

    Development Readiness

    That space—where molecules succeed or fail—is where we operate.

    Build the next generation
    of therapeutic assets with
    us

    Whether you are advancing a novel molecule, reviving a stalled
    programme, or exploring new delivery strategies—we provide the
    scientific and translational architecture to move forward with confidence.

    Advancing a novel molecule

    Reviving a stalled programme

    Exploring new delivery strategies

    Explore
    Drag